poisar

Stocks · News reference

Sionna Therapeutics To Advance SION-451/SION-2222 CF Combo Into Phase 2a; Cuts Workforce By 46% To Extend Cash Runway Into The Second Half Of 2029

BenzingaBenzinga Newsdesk

Post hoc analyses of SION-719 PreciSION CF subset showed a mean placebo-adjusted sweat chloride reduction of up to -8.6 mmol/L consistent with NBD1 biological activityDual combination Phase 2a trial expected to initiate

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncNa

    Sionna Therapeutics Reports Third Quarter 2026 Financial Results

    Sionna Therapeutics announced it will advance its SION-451 + SION-2222 dual combination into the AscenSION CF Phase 2 proof-of-concept trial, expected to initiate in Q1 2027. The company reported a strong cash position of $249.8 million as of September 30, 2026, expected to fund operations into the second half of 2029. However, the company implemented a 46% workforce reduction in September 2026 to focus resources on the dual combination program and extend its operating runway.